NCT07229638 2026-03-12
A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
Clinical Trials
21 trialsNCT03723291 2026-03-03
PITSTOP
University College, London
Phase 1 Completed
NCT07394946 2026-02-20
NELOPHER
Cancer Care Hospital & Research Centre Foundation, Lahore
Phase 2 Not yet recruiting
NCT02303821 2025-06-04
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Amgen
Phase 1 Completed
NCT04049747 2025-03-24
IP4-CHRONOS
Imperial College London
Phase NA Completed
NCT06726369 2025-03-13
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Recruiting
NCT04239599 2022-09-29
RCT-PHART2
Sunnybrook Health Sciences Centre
Phase NA Unknown
NCT02412878 2022-09-23
ARROW
Amgen
Phase 3 Completed
NCT02335983 2020-11-06
Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Amgen
Phase 1 Completed
NCT01335893 2018-02-05
Intraoperative Imaging of Thoracic Malignancies With Indocyanine Green
University of Pennsylvania
Phase 1 Completed
NCT00511238 2017-08-31
Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
Amgen
Phase 2 Completed
NCT01980589 2017-05-30
CHAMPION 2
Amgen
Phase 1 Completed
NCT00530816 2017-05-02
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
Amgen
Phase 2 Completed
NCT01949545 2017-05-02
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
Amgen
Phase 1 Completed
NCT00441870 2012-03-09
Study of EC0225 for the Treatment of Refractory or Metastatic Tumors
Endocyte
Phase 1 Completed
NCT00083993 2011-11-08
Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3 Terminated
NCT00051974 2008-02-11
Phase 2 Study of VELCADE Alone or VELCADEĀ® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT00051987 2008-02-11
Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT00063713 2008-02-11
VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT00064610 2008-02-11
Phase I/II Dose Escalation Study of VELCADEĀ® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer
Millennium Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT00064636 2005-06-24
Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Millennium Pharmaceuticals, Inc.
Phase 1 Terminated